FINWIRES · TerminalLIVE
FINWIRES

BQE Water's Q4 Profit Rises on Higher Revenue

By

-- BQE Water (BQE.V) on Thursday reported a 36% rise in its fourth-quarter profit on higher revenue.

Net income for the three months ended Dec. 31 rose to $1.65 million from $1.21 million in the same period a year earlier.

Revenue for the quarter rose to $7.50 million from $5.09 million in the prior-year period.

In its 2026 outlook, the company said it has "good visibility and certainty over several larger technical services contracts and expect strong results in the first half of 2026". It added operations services for the emergency treatment system at Eagle Mine will continue until June 2026. "Since we do not have an agreement to operate the system for more than 6 months, we will continue to report this project under technical services," it added.

BQE noted its new aquatic toxicology laboratory will become operational and be able to perform a range of specialized investigative tests in prior to the end of the second quarter.

"Building on our strong growth throughout the year, we closed out the fourth quarter achieving new records across nearly every key metric in our annual results. During the fourth quarter, we completed the operating season at Eagle Mine discharging over 1 million cubic meters of clean water for emergency treatment and mobilized our team to be ready to operate the 20-year operations service contract at the Britannia Mine treatment plant," said chief executive David Kratochvil.

"It will be another growth year in 2026 for BQE, as we anticipate continuing our emergency treatment at Eagle, restarting/resuming operations at the 7 sites we operated in 2025, and taking over operations at 4 additional treatment plants in BC, Quebec, and the Yukon."

Shares of the company closed up $0.50 at $73 on TSX Venture Exchange.

Related Articles

Asia

Electro Optic Systems Reports Contract Backlog Growth as of March 31

Electro Optic Systems Holdings (ASX:EOS) reported a contract backlog of AU$518 million as of March 31, up 13% from the end of 2025, according to a Thursday filing with the Australian bourse.The company closed the March quarter with unrestricted cash holdings of AU$95.1 million, representing a decrease of AU$11.8 million from the end of 2025, per the filing.

$ASX:EOS
Asia

Regis Healthcare Expects Fiscal 2026 Underlying EBITDA at Top End of Guidance

Regis Healthcare (ASX:REG) said it expects fiscal 2026 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) of about AU$135 million, at the top end of guidance, according to a Thursday Australian bourse filing.Occupancy across mature homes averaged about 96% in the fiscal third quarter, per the filing.The company said it generated net refundable accommodation deposit (RAD) cash inflows of AU$44.5 million in the third quarter, taking the total net RAD cash inflows for the year to date to AU$223 million.As resident turnover occurs, the progressive repricing of existing paid-up RADs to current advertised room prices is expected to generate net operating cash inflows of about AU$400 million over time while also increasing RAD retention earnings, the company added.

$ASX:REG
Research

Research Alert: CFRA Keeps Hold Opinion On Shares Of Mondelez International

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price of $63, raised $1, reflects a 19x multiple of projected 2027 EPS, in line with MDLZ's historical forward P/E average. We raise our 2026 EPS estimate by $0.06 to $3.08, but cut 2027's by $0.11 to $3.32. We continue to see headwinds related to chocolate and biscuits divisions, though favorable forex has been helping to a degree. MDLZ highlighted plans to stimulate growth with more promotional activity, which could boost revenues (we see an acceleration in revenues in 2027), but may come with the trade-off of narrower margins. We note that cost-saving efforts can also contribute to staving off some of the margin pressure. MDLZ is largely hedged on its cocoa input costs for 2026 but less so in 2027. Thus, if the substantial rise in cocoa pricing in 2025 does not reemerge, it should help the bottom line in 2027 as cost pressures should ease. Share buybacks have also contributed to EPS, and we note that Q1 2026 share count was down 1.5% from one year earlier.

$MDLZ